Fortrea
Rating
Key Statistics
Market Data
Valuation (TTM)
Valuation (NTM)
Cash Flow
Margins
Growth (CAGR)
Returns
Financial Health
Dividends
Profile
Fortrea Holdings Inc. functions as a global contract research organization (CRO), concentrating on providing development services for biopharmaceutical products and medical devices. The company's oper...
Latest News
3 days ago · seekingalpha.com
Fortrea: A Promising Turnaround At An Attractive ValuationFortrea Holdings (FTRE) receives a buy rating due to operational restructuring, improving profitability, and a positive new orders trend despite ongoing revenue decline. FTRE's Q3 2026 results show adjusted EBITDA up 14.4% to $58M, with adjusted EPS rising to $0.28, reflecting effective expense management. The book-to-bill ratio of 1.12x and expanded early clinical trials capacity signal revenue stabilization and growth potential, though backlog quality remains a key watchpoint.
19 days ago · marketbeat.com
What Fortrea (FTRE) Said on Its Q3 Earnings CallFortrea NASDAQ: FTRE reported third-quarter 2026 revenue of $691.5 million, down 1.4% from a year earlier but up 2.0% sequentially, as the contract research organization cited improving demand, stronger operational execution and continued cost discipline.
19 days ago · seekingalpha.com
Fortrea Holdings Inc. (FTRE) Q3 2026 Earnings Call TranscriptFortrea Holdings Inc. (FTRE) Q3 2026 Earnings Call Transcript
19 days ago · zacks.com
Fortrea Holdings Inc. (FTRE) Q3 Earnings and Revenues Surpass EstimatesFortrea Holdings Inc. (FTRE) came out with quarterly earnings of $0.28 per share, beating the Zacks Consensus Estimate of $0.24 per share. This compares to earnings of $0.12 per share a year ago.
19 days ago · globenewswire.com
Fortrea Reports Third Quarter 2026 ResultsSustained commercial momentum, continued margin improvement, and targeted investments strengthen growth foundation Sustained commercial momentum, continued margin improvement, and targeted investments strengthen growth foundation
21 days ago · globenewswire.com
Fortrea to Participate in Jefferies Global Healthcare ConferenceDURHAM, N.C., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE), a leading global contract research organization (“CRO”), today announced that CEO Anshul Thakral, CFO Jason Knoblauch, and SVP of Investor Relations Tracy Krumme will participate in the following conference:
25 days ago · globenewswire.com
Fortrea and Omico Collaboration to Advance Biomarker-led Oncology Drug DevelopmentCollaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia Collaboration aims to improve trial planning and expand patient access to biomarker-matched studies in Australia
26 days ago · zacks.com
Fortrea Holdings Inc. (FTRE) Earnings Expected to Grow: Should You Buy?Fortrea Holdings Inc. (FTRE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
28 days ago · globenewswire.com
Fortrea Completes Acquisition of the Early Phase Services Division from Worldwide Clinical TrialsHighlights Fortrea completes acquisition of the Early Phase Services division from Worldwide Clinical Trials Adds a 60,000-square-foot GLP-compliant bioanalytical laboratory in Austin, Texas; a 200-bed GCP-compliant clinical pharmacology unit in San Antonio, Texas; and a biospecimen storage facility in Pflugerville, Texas Expands Fortrea's early clinical development capacity to more than 570 beds globally and adds dedicated large and small molecule bioanalytical capabilities Enables more integrated execution of early-phase studies by reducing operational handoffs between clinical and bioanalytical functions Strengthens Fortrea's end-to-end clinical development platform supporting clients from first-in-human studies through Phase IV and post-approval evidence generation Supports Fortrea's growth strategy by scaling early clinical development capabilities, increasing clinical research unit capacity and enhancing the company's ability to create long-term value for shareholders Provides continuity of operations, study delivery and client support throughout the transition through a strategic alliance agreement between the companies DURHAM, N.C., Oct. 19, 2026 (GLOBE NEWSWIRE) -- Fortrea (Nasdaq: FTRE) (the “Company”), a leading global contract research organization (“CRO”), today announced it has completed its acquisition of the Early Phase Services division from Worldwide Clinical Trials.
1 month ago · seekingalpha.com
3 Top Small-Cap Stocks With Market-Beating MomentumSmall-cap stocks have surrendered their lead over large caps in 2026 amid rising Treasury yields, but historical data shows small caps can rebound strongly when yields decline. Bank of America strategists see potential for a small-cap rebound if the 10-year Treasury yield peaks around their year-end forecast of 5%. I highlight three fundamentally strong small-cap stocks that have outperformed the market since the Russell 2000's recent high, defying the index's broader weakness.
Earnings
Analyst Summary
Add to Watchlist
Select watchlists to add or remove FTRE